Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 21 January 2026, 15:44 HKT/SGT
Share:
    

Source: Eisai
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Highest ranked global pharmaceutical company

TOKYO, Jan 21, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s tenth inclusion on the list. Ranked 36th, Eisai is the highest ranking among global pharmaceutical companies as well as the highest ranking Japanese company listed in the Global 100 (please visit here for the Global 100 ranking).

The Global 100 evaluates the sustainability of more than 8,200 of the world’s major corporations based on the United Nation’s Sustainable Development Goals (SDGs). Since 2005, companies ranking among the top 100 in the world have been announced each year. The Global 100 companies are evaluated for sustainable revenue and its growth, and sustainable investment as defined by Corporate Knights based on publicly disclosed data from financial filings, integrated reports, or other such channels. Eisai was highly evaluated, particularly in indicators such as sustainable revenue and investment achieved through business activities, and its system reflecting sustainability targets in executive compensation.

Eisai’s corporate concept is to give first thought to patients and the people in the daily living domain, and increase the benefits that health care provides to them as well as meet their diversified healthcare needs worldwide. Based on this human health care (hhc) corporate concept, Eisai is striving to sustainably enhance corporate value by strengthening its sustainability initiatives and increasing non-financial value.

Media Inquiries:

Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 10, 2026 12:34 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
Feb 6, 2026 10:31 HKT/SGT
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
Jan 26, 2026 10:37 HKT/SGT
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Jan 13, 2026 08:50 HKT/SGT
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 6, 2026 09:43 HKT/SGT
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Dec 11, 2025 18:41 HKT/SGT
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 9, 2025 17:51 HKT/SGT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 4, 2025 17:36 HKT/SGT
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 3, 2025 17:19 HKT/SGT
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 2, 2025 23:01 HKT/SGT
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: